Physician profile
Kate M Smith
NPI 1861431462
$5,616.24
in general payments reported to CMS, 2019-2025
26 companies · $1,708 in 2025
The $1,708 reported for 2025 was more than what 92% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,047 · 2022: $1,027 · 2023: $921 · 2024: $912 · 2025: $1,708.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,542.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,541.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,443.23 | 2021-2025 | Breztri, Airsupra, Farxiga |
| Novo Nordisk INC | $837.14 | 2021-2025 | Wegovy, Rybelsus, Ozempic |
| Glaxosmithkline, LLC. | $517.80 | 2022-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Abbvie INC. | $455.73 | 2021-2024 | |
| Lilly USA, LLC | $434.96 | 2021-2025 | Kisunla, Zepbound, Jardiance |
| Eisai INC. | $349.30 | 2021-2025 | |
| Phathom Pharmaceuticals, INC. | $210.93 | 2023-2024 | Voquezna |
| Otsuka America Pharmaceutical, INC. | $195.78 | 2021-2025 | Rexulti |
| Stryker Corporation | $161.25 | 2025 | Flowtriever |
| Esperion Therapeutics, INC. | $140.66 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $133.15 | 2021 | |
| Abbott Laboratories | $123.06 | 2021-2022 | |
| Vanda Pharmaceuticals INC. | $93.02 | 2025 | Fanapt |
| Amgen INC. | $89.04 | 2025 | Repatha |
| Alkermes, INC. | $79.65 | 2023 | Lybalvi |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $68.36 | 2021-2025 | |
| Lundbeck LLC | $62.02 | 2025 | Rexulti |
| Sanofi-Aventis U.S. LLC | $36.18 | 2021-2022 | |
| Exact Sciences Corporation | $33.58 | 2023-2025 | Cologuard Collection Kit |
| Lifescan, INC. | $29.71 | 2021 | |
| Supernus Pharmaceuticals, INC. | $28.00 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $21.71 | 2021 | |
| Janssen Pharmaceuticals, INC | $20.65 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $19.76 | 2021 | |
| Dexcom, INC. | $17.28 | 2025 | Dexcom G6 Transmitter |
| Takeda Pharmaceuticals U.S.A., INC. | $14.29 | 2025 | Gattex |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kate Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.